Mindblown: a blog about philosophy.
-

Uber Earnings Q2 2026: Revenue Rises, Profit Grows, Stock Falls
Uber posted higher profits and record cash flow, but weaker guidance overshadowed strong results. Here’s what investors should know.
-

Shopify Delivers Strong Q2 Results as Revenue and Profit Rocket
Shopify beat earnings and revenue expectations as merchant activity surged. Here’s why its strong outlook could support more growth ahead.
-

AMD Stock Drops After Q2 Earnings, But Wall Street Still Sees Strong Upside
AMD beat earnings but its stock still fell. Here’s why Wall Street analysts remain bullish and see long-term AI-driven growth ahead.
-

McDonald’s Stock Hits 2-Year Low, But Valuation Looks Fair
McDonald’s beat depressed expectations and offers investors a fairer entry point than they’ve had in years.
-

Missed My Earlier Oracle Trade? Here’s Another Chance to Bid Up ORCL Stock.
In mid-July, Oracle stock was projected to reach $140 later in August, based on Markov simulation results. Now, there’s another compelling idea to consider.
-

When Did Palantir Stop Being A Pentagon Story?
Palantir’s commercial business is accelerating at a remarkable pace, reshaping the investment story beyond government contracts and AI hype.
-

Spotify’s Miss Buried Its Most Important Number In It’s Q2 Earnings Report
Spotify stock fell after an earnings miss, but strong Premium growth, rising ARPU, and solid cash flow suggest the long-term story remains strong.
-

Snap Has a Strong Q2 as Advertising and AI Help the Company Grow
Snap beat earnings estimates as AI-powered advertising, rising user growth, and a strong outlook fueled optimism for continued growth in 2026.
-

Palantir Technologies is Still One of the World’s Biggest AI Beneficiaries
Palantir crushed earnings estimates, raised guidance, and posted record AI-driven growth as commercial demand and government contracts surged.
-

CRISPR Therapeutics Stock: CASGEVY Growth Signals Bigger Move Ahead
CRISPR Therapeutics’ earnings report confirmed what investors suspected. CASGEVY is finally translating clinical validation into commercial traction
Got any book recommendations?